ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2212 entries already.
Therapies for autoreactive immune disorders have greatly advanced in the past decades but often have significant side effects. Marinomed Biotech AG strives to improve therapies by increasing the solubility and bioavailability of existing drugs. A proprietary pipeline and Solv4U, a B2B offering for API solubilization, enable the development of clinically meaningful new or improved therapies.
Finnish Solar Foods Ltd has got the first ever novel food authorisation for its microbially-produced protein powder Solein.
After two years online, PharmaLab 2022 returns on site for its 10th edition. Over three days, the congress will offer the opportunity to share the latest experiences with colleagues and to exchange ideas in person.
Bone Therapeutics has merged with French inflammatory/autoimmune company Medsenic in a €40m deal and changed its name into BioSenic.
Molecular cartography company Resolve Biosciences has raised $71m in series B funding co-led by Patient Square Capital, EDBI, Alafi Capital and NRW.BANK as well as other existing investors.
Cambridge-based Enhanc3D Genomics Ltd has raised £10m in Series A financing led by BGF and Parkwalk Advisors.
Belgian CDMO Univercells SA has raised €44m through the first close of its Series D financing round led by Belgian and international investors. I
Most people know Switzerland for its watches, mountains, and chocolate. But biopharma professionals know that this country in the heart of Europe offers much more: the ideal setting for innovation and production in the fields of pharma and biotech.
German Adrenomed AG has got a recommendation from the EMA to push its Adrenomedullin-binding antibody Adrecizumab into a pivotal Phase III study.
The CRO industry is predicted to grow considerably over the next five years. Trials are becoming more complex, and technology is becoming increasingly interwoven with processes. The CRO of tomorrow must be tech smart, agile, and environmentally conscious to remain relevant. In this changing landscape, how does a CRO cut through the noise in 2022-30?